This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Angion Biomedica Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Angion Biomedica.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	21.3%
Revenue growth rate	-122.1%
Future return on equity	n/a
Analyst coverage	Low
Last updated	01 May 2023

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:5YX - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	N/A	N/A	N/A	N/A	1
12/31/2024	N/A	N/A	N/A	N/A	1
12/31/2023	N/A	N/A	N/A	N/A	1
3/31/2023	1	-29	-31	-31	N/A
12/31/2022	2	-39	-38	-38	N/A
9/30/2022	28	-17	-48	-48	N/A
6/30/2022	30	-24	-55	-55	N/A
3/31/2022	30	-32	-56	-56	N/A
12/31/2021	28	-55	-53	-53	N/A
9/30/2021	3	-98	-18	-18	N/A
6/30/2021	2	-100	-25	-24	N/A
3/31/2021	2	-104	-27	-27	N/A
12/31/2020	3	-80	-23	-23	N/A
9/30/2020	3	-67	-48	-48	N/A
12/31/2019	1	-41	-25	-25	N/A
12/31/2018	4	-25	-8	-8	N/A
6/30/2014	6	0	N/A	1	N/A
3/31/2014	6	0	N/A	2	N/A
12/31/2013	7	1	N/A	2	N/A
12/31/2012	7	0	N/A	1	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 5YX's forecast earnings growth is above the savings rate (0.2%).

Earnings vs Market: Insufficient data to determine if 5YX's earnings are forecast to grow faster than the German market

High Growth Earnings: Insufficient data to determine if 5YX's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 5YX is forecast to have no revenue next year.

High Growth Revenue: 5YX is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 5YX's Return on Equity is forecast to be high in 3 years time

This company is no longer active

Angion Biomedica Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Elicio Therapeutics, Inc. completed the acquisition of Angion Biomedica Corp. (NasdaqGS:ANGN) from Vifor (International) AG, Eisa-Abc LLC and others in a reverse merger transaction.

First quarter 2023 earnings released: US$0.15 loss per share (vs US$0.47 loss in 1Q 2022)

Insufficient new directors

Elicio Therapeutics, Inc. entered into a definitive merger agreement to acquire Angion Biomedica Corp. (NasdaqGS:ANGN) in a reverse merger transaction.

Angion Biomedica Receives Nasdaq Notice Regarding Minimum Bid Price Requirements

Third quarter 2022 earnings released: US$0.30 loss per share (vs US$0.53 loss in 3Q 2021)

Second quarter 2022 earnings released: US$0.30 loss per share (vs US$0.57 loss in 2Q 2021)

Angion Biomedica Corp. Announces Resignation of John F. Neylan as Chief Medical Officer and Head of Research, Effective on August 15, 2022

Angion Biomedica Corp. Announces Discontinuation of Phase 2 Trial of ANG-3070 in Patients with Primary Proteinuric Kidney Disease

President recently bought €95k worth of stock

Angion Announces Phase 1b Trial of ANG-3070 in Patients with Idiopathic Pulmonary Fibrosis

First quarter 2022 earnings released: US$0.47 loss per share (vs US$1.57 loss in 1Q 2021)

Full year 2021 earnings released: US$1.93 loss per share (vs US$5.43 loss in FY 2020)

Angion Biomedica Corp. Provides ANG-3070 Program Update

President recently bought €646k worth of stock

President recently bought €94k worth of stock

Angion Biomedica Corp. and Vifor Pharma AG Report Topline Results from Phase 2 Guard Trial of ANG-3777 in Cardiac Surgery-Associated Acute Kidney Injury

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies